Oruka Therapeutics, Inc.ORKA
Price (close)
$85.49
Market cap
$5.7B
P/E
—
Revenue (TTM)
—
Net income
-$132.9M
Dividend yield
—
1-year total return
468.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Oruka Therapeutics, Inc. does.
pursuant to an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (the “Merger Agreement”). Following
the transactions contemplated by the Merger Agreement, Pre-Merger Oruka merged with and into Atlas Merger Sub Corp., a wholly owned subsidiary
of ARCA biopharma, Inc. (“ARCA”) and following that, Pre-Merger Oruka then merged with and into Atlas Merger Sub II, LLC (“Second
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Net income | -$9.7M | -$19.3M | -$9.9M | -$5.3M | — | -$105.4M |
| Free cash flow | -$7.7M | -$18.8M | -$10.9M | -$5.0M | — | -$88.4M |
More on ORKA.
- Oruka Therapeutics, Inc. summary
- Oruka Therapeutics, Inc. financial statements
- Oruka Therapeutics, Inc. key metrics
- Oruka Therapeutics, Inc. health scores and style box
- Oruka Therapeutics, Inc. earnings
- Oruka Therapeutics, Inc. dividends
- Oruka Therapeutics, Inc. valuation
- Oruka Therapeutics, Inc. ownership and insiders
- Oruka Therapeutics, Inc. peers
Figures from Oruka Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.